Silverarc Capital Management LLC Raises Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Silverarc Capital Management LLC raised its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 24.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,120,473 shares of the company's stock after acquiring an additional 219,344 shares during the quarter. UroGen Pharma comprises approximately 2.6% of Silverarc Capital Management LLC's portfolio, making the stock its 13th biggest holding. Silverarc Capital Management LLC owned approximately 4.78% of UroGen Pharma worth $11,933,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its stake in shares of UroGen Pharma by 5.9% during the 3rd quarter. State Street Corp now owns 769,583 shares of the company's stock valued at $9,774,000 after purchasing an additional 42,907 shares during the period. Barclays PLC increased its position in shares of UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after buying an additional 48,040 shares during the period. Geode Capital Management LLC lifted its holdings in shares of UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after buying an additional 34,248 shares in the last quarter. Tidal Investments LLC boosted its position in shares of UroGen Pharma by 19.1% in the third quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock valued at $477,000 after acquiring an additional 6,030 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after acquiring an additional 49,318 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

Insiders Place Their Bets

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company's stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on URGN. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. The Goldman Sachs Group lowered their price objective on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. HC Wainwright reduced their target price on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Scotiabank started coverage on UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price on the stock. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Monday, March 10th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, UroGen Pharma presently has a consensus rating of "Buy" and a consensus price target of $32.86.

UroGen Pharma Trading Down 2.4 %

Shares of NASDAQ URGN traded down $0.24 during mid-day trading on Friday, hitting $9.87. The stock had a trading volume of 264,533 shares, compared to its average volume of 519,448. The firm has a market cap of $454.95 million, a P/E ratio of -3.13 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business has a 50 day moving average price of $10.43 and a two-hundred day moving average price of $11.09. UroGen Pharma Ltd. has a 1 year low of $8.94 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million. On average, equities analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.